imatinib mesylate has been researched along with Arterial Occlusive Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buschmann, I; Dombret, H; Dörken, B; Giles, FJ; Grille, P; Haverkamp, W; Kim, TD; Labussière, H; le Coutre, PD; Levato, L; Lindhorst, R; Mirault, T; Nicolini, FE; Rea, D; Rosti, G; Schwarz, M | 1 |
| Giles, FJ; Hochhaus, A; Hong, F; le Coutre, PD; Mauro, MJ; McNeill, C; Ortmann, CE; Saglio, G; Woodman, RC | 1 |
| Abe, K; Alvarez, D; Alzoubi, A; Järvinen, TA; Komatsu, M; Mann, D; McMurtry, IF; O'Neill, K; Oka, M; Ruoslahti, E; Toba, M; Urakami, T | 1 |
| Marin, D | 1 |
| Bachmeyer, C; Garandeau, E; Lecomte, I; Lionnet, F; Stankovic Stojanovic, K; Thiolière, B | 1 |
| Bessler, WK; Clapp, DW; Conway, SJ; Horn, WE; Ingram, DA; Lasater, EA; Li, F; Mead, LE | 1 |
1 review(s) available for imatinib mesylate and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Asthenia; Benzamides; Bone Marrow Examination; Cytogenetic Analysis; Drug Administration Schedule; Drug Substitution; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome | 2014 |
5 other study(ies) available for imatinib mesylate and Arterial Occlusive Diseases
| Article | Year |
|---|---|
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Cohort Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peripheral Arterial Disease; Piperazines; Pyrimidines | 2013 |
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Pyrimidines; Retrospective Studies | 2013 |
A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Topics: Administration, Sublingual; Amino Acid Sequence; Animals; Arterial Occlusive Diseases; Benzamides; Drug Delivery Systems; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Imatinib Mesylate; Infusions, Intravenous; Injections, Intravenous; Male; Molecular Sequence Data; Peptides; Piperazines; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vasodilator Agents | 2014 |
Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence | 2011 |
Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway.
Topics: Animals; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Cardiovascular Diseases; Carotid Arteries; Cell Proliferation; Cerebrovascular Disorders; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Genes, Neurofibromatosis 1; Imatinib Mesylate; Mice; Mice, Mutant Strains; Neurofibromatosis 1; Piperazines; Pyrimidines; Tunica Intima | 2008 |